On August 6, 2025, BioXcel Therapeutics announced a study published in Frontiers in Pharmacology showing that Dexmedetomidine, the active ingredient in BXCL-501, effectively manages stress-related behaviors, suggesting promising applications for psychiatric disorders. Key findings highlight its strong potency, consistent effects across stress models, and favorable safety profile.